bluebird bio (NASDAQ:BLUE) – Analysts at Cantor Fitzgerald increased their FY2018 EPS estimates for bluebird bio in a research report issued to clients and investors on Tuesday, May 22nd. Cantor Fitzgerald analyst E. Piros now forecasts that the biotechnology company will post earnings per share of ($10.22) for the year, up from their prior estimate of ($10.89). Cantor Fitzgerald has a “Underweight” rating on the stock.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.01) by ($0.30). bluebird bio had a negative return on equity of 27.61% and a negative net margin of 857.55%. The business had revenue of $15.96 million during the quarter, compared to analyst estimates of $5.85 million. During the same quarter last year, the firm posted ($1.68) EPS. The company’s revenue was up 133.7% compared to the same quarter last year.
Several other research analysts have also recently commented on BLUE. Leerink Swann cut bluebird bio from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $162.00 to $194.00 in a research note on Thursday, January 25th. BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Canaccord Genuity reiterated a “buy” rating and issued a $250.00 price target on shares of bluebird bio in a research note on Thursday, February 1st. Sanford C. Bernstein reiterated a “hold” rating and issued a $211.00 price target (up previously from $153.00) on shares of bluebird bio in a research note on Thursday, February 22nd. Finally, BMO Capital Markets set a $222.00 price target on bluebird bio and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $195.80.
bluebird bio opened at $187.00 on Thursday, MarketBeat Ratings reports. bluebird bio has a one year low of $74.45 and a one year high of $236.17. The stock has a market capitalization of $9.30 billion, a P/E ratio of -24.25 and a beta of 2.17.
In other news, insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $200.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider now directly owns 32,522 shares of the company’s stock, valued at $6,504,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Vachon sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $214.38, for a total value of $1,286,280.00. Following the transaction, the director now directly owns 7,000 shares of the company’s stock, valued at $1,500,660. The disclosure for this sale can be found here. Insiders have sold 46,250 shares of company stock valued at $8,269,990 over the last ninety days. Corporate insiders own 3.00% of the company’s stock.
Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. grew its holdings in shares of bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 612 shares during the last quarter. NuWave Investment Management LLC bought a new position in shares of bluebird bio during the fourth quarter valued at approximately $135,000. Wealthcare Advisory Partners LLC bought a new position in shares of bluebird bio during the first quarter valued at approximately $171,000. D.A. Davidson & CO. bought a new position in shares of bluebird bio during the fourth quarter valued at approximately $214,000. Finally, Laurel Wealth Advisors Inc. bought a new position in shares of bluebird bio during the first quarter valued at approximately $215,000.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.